Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,473
Recruiting: 1,285
Ph III recruiting: 130
Growth YoY: +6.4%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,641)

clinicaltrialsPublishedShowing 101–150 of 462 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06001385	HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE)	active not recruiting	Phase 2	313	Center for International Blood and Marrow Transplant ResearchNETWORK	1	Aug 17, 2026	clinicaltrials
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	active not recruiting	Phase 2	68	National Cancer Institute (NCI)